Exenatide improves postprandial hyperglycaemia and dyslipidaemia in metformin treated patients with type 2 diabetes

被引：0
|
作者：
Bunck, M. C. [1 ]
Corner, A. [2 ]
Diamant, M. [1 ]
Eliasson, B. [3 ]
Malloy, J. L. [4 ]
Shaginian, R. M. [5 ]
Deng, W. [4 ]
Kendall, D. M. [4 ]
Smith, U. [3 ]
Yki-Jarvinen, H. [2 ]
Heine, R. J. [1 ]
Taskinen, M. R. [2 ]
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Ctr Diabet, Dept Endocrinol, Amsterdam, Netherlands
[2] Helsinki Univ Hosp, Dept Med, Helsinki, Finland
[3] Sahlgrens Univ Hosp, Lundberg Lab Diabet Res, Gothenburg, Sweden
[4] Amylin Pharmaceut Inc, San Diego, CA USA
[5] Eli Lilly & Co, Nederland, Houten, Netherlands
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
879
引用
收藏
页码：S351 / S351
页数：1
相关论文
共 50 条
  • [1] Exenatide improves postprandial hyperglycemia and dyslipidemia in metformin treated patients with type 2 diabetes
    Bunck, Mathijs C.
    Corner, Anja
    Diamant, Michaela
    Eliasson, Bjorn
    Malloy, Jaret L.
    Shaginian, Rimma M.
    Ding, Wei
    Kendall, David M.
    Smith, Ulf
    Yki-Jarvinen, Hannele
    Heine, Robert J.
    Taskinen, Marja-Ritta
    DIABETES, 2008, 57 : A33 - A33
  • [2] Mathematical modeling shows exenatide improved postprandial β-cell function in patients with type 2 diabetes treated with merformin or metformin and sulfonylurea
    Mari, A
    Halseth, A
    Nanayakkara, N
    Nielsen, L
    Defronzo, R
    Ferrannini, E
    DIABETES, 2005, 54 : A119 - A119
  • [3] Predictors of postprandial hyperglycaemia in patients with type 2 diabetes
    Nita, C. A.
    Rusu, A.
    Bala, C. G.
    Hancu, N.
    DIABETOLOGIA, 2008, 51 : S430 - S430
  • [4] One year treatment with exenatide improves β cell function and glycaemic control in metformin treated type 2 diabetes patients
    Bunck, M. C.
    Diamant, M.
    Corner, A.
    Eliasson, B.
    Malloy, J. L.
    Shaginian, R. M.
    Deng, W.
    Kendall, D. M.
    Taskinen, M.-R.
    Smith, U.
    Yki-Jarvinen, H.
    Heine, R. J.
    DIABETOLOGIA, 2007, 50 : S111 - S112
  • [5] One Year Exenatide Therapy, Compared with Insulin Glargine, Reduces Postprandial Oxidative Stress in Metformin-Treated Patients with Type 2 Diabetes
    Bunck, Mathijs C.
    Corner, Anja
    Eliasson, Bjorn
    Wu, Yan
    Shaginian, Rimma M.
    Yan, Ping
    Heine, Robert J.
    Smith, Ulf
    Yki-Jaervinen, Hannele
    Taskinen, Marja-Riitta
    Diamant, Michaela
    DIABETES, 2009, 58 : A147 - A147
  • [6] EXENATIDE VERSUS INSULIN GLARGINE IN TYPE 2 DIABETES INADEQUATELY TREATED WITH METFORMIN
    Polyzos, S. A.
    Zografou, I.
    Karagianni, P.
    Kartali, N. I. K. I.
    Sampanis, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2015, 17 : A50 - A50
  • [7] Mathematical modeling shows exenatide improved β-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea
    Mari, A.
    Nielsen, L. L.
    Nanayakkara, N.
    DeFronz, R. A.
    Ferrannini, E.
    Halseth, A.
    HORMONE AND METABOLIC RESEARCH, 2006, 38 (12) : 838 - 844
  • [8] Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated?
    Charpentier, G
    Riveline, JP
    Dardari, D
    Varroud-Vial, M
    DRUGS, 2006, 66 (03) : 273 - 286
  • [9] Should Postprandial Hyperglycaemia in Prediabetic and Type 2 Diabetic Patients be Treated?
    Guillaume Charpentier
    Jean-Pierre Riveline
    Dured Dardari
    Michel Varroud-Vial
    Drugs, 2006, 66 : 273 - 286
  • [10] Contributions of fasting and postprandial hyperglycaemia in type 2 diabetes
    Reznik, Y.
    Habteab, A.
    Castaneda, J.
    Shin, J.
    Joubert, M.
    DIABETOLOGIA, 2017, 60 : S36 - S36
12345